Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?
- PMID: 27916675
- DOI: 10.1016/j.ijid.2016.11.416
Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?
Abstract
Tuberculosis (TB) is a priority in terms of incidence and mortality, with about 10.4 million new incident cases and 1.8 million deaths in 2015. The End-TB strategy recently launched by the World Health Organization in the context of the post-2015 agenda, aimed to achieve TB elimination, represents an evolution of the previous historical strategies originally aimed to achieve TB control. Globally, the current decline in TB incidence is rather slow at approximately 1,5% per year to reach the TB pre-elimination phase by 2035 (A more aggressive approach based on diagnosis and treatment of latently infected individuals has been proposed in the context of TB elimination to ensure future generations free of TB. We describes 4 scenarios which, combined, describe the TB epidemiology in a given setting: 1) in absence of interventions, 2) with early TB diagnosis and effective treatment, 3) with irregular TB treatment, 4) with TB co-infected by HIV not undergoing anti-retroviral treatment. To achieve TB Elimination, a more concerted action by funders and governments will be required for further investments into TB prevention, detection and treatment.
Keywords: Elimination; LTBI; MDR-TB; Strategy; Tuberculosis.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.J Assoc Physicians India. 2006 Mar;54:219-34. J Assoc Physicians India. 2006. PMID: 16800350
-
Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination.Eur Respir J. 2013 Sep;42(3):785-801. doi: 10.1183/09031936.00205512. Epub 2013 Feb 8. Eur Respir J. 2013. PMID: 23397299
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Tuberculosis eradication versus control.Int J Infect Dis. 2017 Mar;56:10-13. doi: 10.1016/j.ijid.2016.11.007. Epub 2016 Nov 18. Int J Infect Dis. 2017. PMID: 27872016
-
Tuberculosis elimination: where are we now?Eur Respir Rev. 2018 Jun 13;27(148):180035. doi: 10.1183/16000617.0035-2018. Print 2018 Jun 30. Eur Respir Rev. 2018. PMID: 29898905 Free PMC article. Review.
Cited by
-
Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems.Antibiotics (Basel). 2022 Jun 15;11(6):806. doi: 10.3390/antibiotics11060806. Antibiotics (Basel). 2022. PMID: 35740212 Free PMC article. Review.
-
Designing of phenol-based β-carbonic anhydrase1 inhibitors through QSAR, molecular docking, and MD simulation approach.3 Biotech. 2018 May;8(5):256. doi: 10.1007/s13205-018-1278-z. Epub 2018 May 14. 3 Biotech. 2018. PMID: 29765814 Free PMC article.
-
Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection.Front Immunol. 2020 Aug 28;11:1872. doi: 10.3389/fimmu.2020.01872. eCollection 2020. Front Immunol. 2020. PMID: 32983107 Free PMC article.
-
Expression of mycobacterium tuberculosis induced SOCS3 and STAT3 and the implications on innate immunity in TB patients vs healthy contacts in high TB/HIV endemic setting: A cross-sectional analytical study.PLoS One. 2022 Jul 15;17(7):e0263624. doi: 10.1371/journal.pone.0263624. eCollection 2022. PLoS One. 2022. PMID: 35839170 Free PMC article.
-
HupB Is a Bacterial Nucleoid-Associated Protein with an Indispensable Eukaryotic-Like Tail.mBio. 2017 Nov 7;8(6):e01272-17. doi: 10.1128/mBio.01272-17. mBio. 2017. PMID: 29114022 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources